The stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! About 133,224 shares traded hands. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 17.53% since March 9, 2016 and is downtrending. It has underperformed by 24.94% the S&P500.
The move comes after 5 months negative chart setup for the $158.13M company. It was reported on Oct, 12 by Barchart.com. We have $2.61 PT which if reached, will make NASDAQ:ABUS worth $22.14M less.
Analysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to report earnings on November, 3. They expect $-0.57 earnings per share, down 35.71% or $0.15 from last year’s $-0.42 per share. After $-0.35 actual earnings per share reported by Arbutus Biopharma Corp for the previous quarter, Wall Street now forecasts 62.86% negative EPS growth.
Arbutus Biopharma Corp (NASDAQ:ABUS) Ratings Coverage
Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Arbutus Biopharma has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Wednesday, September 2, the company rating was initiated by JMP Securities. Wedbush initiated it with “Outperform” rating and $20 target price in Friday, August 7 report. The firm has “Neutral” rating given on Thursday, June 16 by Chardan Capital Markets. The stock has “Outperform” rating given by RBC Capital Markets on Friday, November 6. The stock has “Market Perform” rating given by Leerink Swann on Friday, August 5. The rating was downgraded by Chardan Capital Markets to “Sell” on Friday, July 8. The firm has “Outperform” rating given on Friday, August 7 by Wedbush. The stock has “Sell” rating given by Chardan Capital Markets on Monday, May 16.
According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”
Another recent and important Arbutus Biopharma Corp (NASDAQ:ABUS) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on December 29, 2013.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.